Skip to content

Repligen RGEN Total Equity

Total Equity at other companies

Revvity logo
RevvityRVTY
$7.18B-5.9%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$51.93B+5.2%
Danaher logo
DanaherDHR
$52.95B+4.1%
Agilent Technologies logo
Agilent TechnologiesA
$7.12B+16.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$6.85B+2.6%
TEC
Bio-TechneTECH

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's total equity?
Repligen (RGEN) reported total equity of $2.11B in Q1 2026.
How has Repligen's total equity changed year-over-year?
Repligen's total equity increased by 6.0% year-over-year, from $1.99B to $2.11B.
What is the long-term trend for Repligen's total equity?
Over 5 years (2020 to 2025), Repligen's total equity has grown at a 6.6% compound annual growth rate (CAGR), from $1.53B to $2.11B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.